2509 — Qyuns Therapeutics Share News
0.000.00%
Last trade - 00:00- HK$3.72bn
- HK$3.31bn
- CNY806.96m
Brief: Qyuns Therapeutics Says Qx027n Obtains Two Clinical Trial Approvals For Copd, Chronic Rhinosinusitis
Brief: Qyuns Therapeutics Says Saifu Juli To Buy 34% Of Cellularforce For RMB86.02 Million
Brief: Qyuns Therapeutics Repurchases 3.43 Million Shares As Treasury Shares From Nov 6, 2025 To June 9
Brief: Qyuns Therapeutics Co Receives Milestone Payment From Roche
Brief: Qyuns Therapeutics To Subscribe PDB Wealth Product With RMB100 Million Principal
Brief: Qyuns Therapeutics Co To Subscribe For PDB Wealth Management Product With RMB100 Million Principal
Brief: Qyuns Therapeutics Says New Drug Application Of Crusekitug (Qx002n) Accepted By NMPA
Brief: Qyuns Therapeutics Enters License & Collaboration Agreement With LE2025 Therapeutics AG
Brief: Qyuns Therapeutics Says Received Milestone Payment Of $5 Million
Brief: Qyuns Therapeutics Says QX027N Injection Obtains Clinical Trial Approvals From Center For Drug Evaluation, NMPA
Brief: Qyuns Therapeutics Repurchased Total 549,800 Ordinary Shares From Nov 6 To Nov 10
Brief: Qyuns Therapeutics Announces Exclusive License Agreement With F. Hoffmann-La Roche
Brief: Qyuns Therapeutics Says To Issue 5 Million Placing Shares At HK$20.0 Per Share
Brief: Qyuns Therapeutics HY Revenue RMB206.5 Million
Brief: Qyuns Therapeutics Subscribes To Wealth Management Products With Principal Amount RMB60 Mln
Brief: Qyuns Therapeutics Enters Exclusive License Agreement With Caldera Therapeutics
Brief: Qyuns Therapeutics Says Founder, Others Voluntarily Undertaken Not To Sell Any Shares Of Co
Brief: Qyuns Therapeutics To Subscribe For Wealth Management Products
Brief: Qyuns Therapeutics Updates On Phase III Clinical Trial Of QX002N